Lifestyle Asset Management Inc. Buys 57,799 Shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY)

Lifestyle Asset Management Inc. raised its stake in shares of Dr. Reddy’s Laboratories Limited (NYSE:RDY) by 422.2% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 71,488 shares of the company’s stock after purchasing an additional 57,799 shares during the quarter. Lifestyle Asset Management Inc.’s holdings in Dr. Reddy’s Laboratories were worth $1,129,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in RDY. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in shares of Dr. Reddy’s Laboratories by 318.0% during the 2nd quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 372,900 shares of the company’s stock worth $28,411,000 after purchasing an additional 283,700 shares during the period. Artemis Investment Management LLP increased its holdings in shares of Dr. Reddy’s Laboratories by 398.3% during the 4th quarter. Artemis Investment Management LLP now owns 295,530 shares of the company’s stock worth $4,666,000 after purchasing an additional 236,224 shares during the period. Fisher Asset Management LLC increased its holdings in shares of Dr. Reddy’s Laboratories by 59.4% during the 3rd quarter. Fisher Asset Management LLC now owns 491,303 shares of the company’s stock worth $39,034,000 after purchasing an additional 183,146 shares during the period. Millennium Management LLC increased its stake in Dr. Reddy’s Laboratories by 61.4% in the second quarter. Millennium Management LLC now owns 332,502 shares of the company’s stock valued at $25,333,000 after acquiring an additional 126,472 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in Dr. Reddy’s Laboratories by 12.8% in the second quarter. Dimensional Fund Advisors LP now owns 1,003,782 shares of the company’s stock valued at $76,455,000 after acquiring an additional 114,294 shares during the period. Institutional investors own 3.85% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on RDY. Barclays lowered their target price on shares of Dr. Reddy’s Laboratories from $17.40 to $17.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 6th. Nomura cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “neutral” rating in a research note on Thursday, December 19th. Finally, StockNews.com cut shares of Dr. Reddy’s Laboratories from a “buy” rating to a “hold” rating in a research note on Friday, December 6th.

Dr. Reddy’s Laboratories Price Performance

NYSE:RDY opened at $14.16 on Friday. The firm has a market cap of $11.82 billion, a PE ratio of 22.61 and a beta of 0.51. Dr. Reddy’s Laboratories Limited has a 12 month low of $13.61 and a 12 month high of $16.89. The company has a quick ratio of 1.36, a current ratio of 1.92 and a debt-to-equity ratio of 0.02. The company’s 50-day moving average price is $14.87 and its two-hundred day moving average price is $15.53.

Dr. Reddy’s Laboratories (NYSE:RDY) last released its quarterly earnings results on Thursday, January 23rd. The company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of $0.19 by $0.01. Dr. Reddy’s Laboratories had a net margin of 17.81% and a return on equity of 18.53%. On average, equities analysts anticipate that Dr. Reddy’s Laboratories Limited will post 0.81 EPS for the current fiscal year.

Dr. Reddy’s Laboratories Profile

Dr. Reddy’s Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company’s Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business.